Ozempic, a prescription GLP-1 drug for type 2 diabetes, has no payout date yet. The injury cases have not reached a court-approved global deal. The Law Office of Melinda J.
Helbock reported in its Oct. 20, 2026 update that no per-claim payout schedule exists Helbock Law's October update. That means readers should follow court milestones, not rumored amounts. The next milestones are expert-evidence rulings and test trials.
Official resources:
- Read the original report from FDA — Use this primary source to review the complete report.
- Read the official notice from Therxindex — Use this primary source to verify the official announcement.
Table of Contents
- Where are the cases right now?
- What must happen before any payout date?
- Which injuries are part of the lawsuits?
- Why do payout rumors mislead?
- What can you do while you wait?
- Frequently Asked Questions
Where are the cases right now?
The gut-injury cases are centralized as MDL 3094 before Judge Karen S. Marston in the Eastern District of Pennsylvania. TortAdvisor, citing the Oct. 1, 2026 federal report, counts 4,025 pending actions TortAdvisor's MDL tracker.
Centralization puts discovery and expert fights in one court. A separate vision-loss track, MDL 3163 for NAION claims, sits before the same judge. Helbock's office reports 247 pending actions as of Oct. 1, 2026. The split matters because gut claims and vision claims may move on different proof and schedules.
What must happen before any payout date?
Judge Marston held a five-day general-causation hearing Sept. 14-18, 2026 and heard closing arguments Oct. 13-14, 2026, according to MDL Update MDL Update's case page. The hearing tested expert testimony under Rule 702 and Daubert.
No ruling had issued at the time of that update. No bellwether trial has been held or scheduled, Helbock's office reports. No GLP-1 case has reached a verdict as of October 2026. Without test verdicts, both sides lack a trial-value benchmark for settlement talks.
Which injuries are part of the lawsuits?
Plaintiffs allege Ozempic, Wegovy, Mounjaro and related GLP-1 drugs caused severe harms without adequate warnings, according to Helbock's office. The gut-injury group centers on gastroparesis, ileus and bowel obstruction. It also includes gallbladder disease and pancreatitis.
The second group centers on sudden vision loss tied to NAION. NAION means reduced blood flow to the optic nerve. Keeping the two tracks separate helps readers match medical records to the right claim path.
Why do payout rumors mislead?
Publicized multi-billion-dollar exposure figures are speculative projections, not court findings, according to The RX Index Research. New lawsuits are still being filed. A growing case count can extend pretrial work rather than speed checks. The FDA issued Warning Letter MARCS-CMS 717576 to Novo Nordisk on March 5, 2026, after a Jan.
13-Feb. 7, 2025 inspection found serious adverse-event reporting violations. That enforcement record is part of the wider dispute. It does not create a payout fund or schedule.
What can you do while you wait?
Use this time to make a future claim review faster. Medical proof will matter more than a filing date alone.
Filing rules and time limits vary by state and injury. Save pharmacy records, hospital notes, and procedure reports in one folder for your lawyer.
- List each GLP-1 drug, dose, pharmacy, and dates used
- Save ER notes, imaging, surgery reports, and eye-exam records
- Keep a short symptom diary with workdays missed and costs paid
- Ask a lawyer handling MDL 3094 or MDL 3163 about deadlines in your state
Frequently Asked Questions
Will stomach claims and vision-loss claims pay on the same timeline?
No. They sit in separate MDL tracks, MDL 3094 and MDL 3163, and may need different expert proof.
Does a larger case count mean checks are near?
No. New filings can extend pretrial work, so watch the Daubert ruling and any bellwether trial dates.
What records help most now?
Drug names and dates, pharmacy records, ER and imaging reports, surgery notes, and eye-exam records.